Light at the end of the COVID-19 Tunnel

Analysis

BaLL LunLa / Shutterstock.com

The past week has seen two dramatic vaccine announcements, by Pfizer and Moderna, each claiming more than 90% efficacy. This is good news; some have even called it the beginning of the end of the COVID pandemic, writes Les Nemethy.

Photo by BaLL LunLa / Shutterstock.com

In this article I try to look at what this news means for company owners and investors, with greater granularity. The vaccines do not constitute an immediate magic bullet, because of challenges in roll-out, and because economic and financial damage has already been done and will continue to be done until the vaccines kicks in; indeed, the virus will be outlived by its economic and financial effects.

Challenges in Roll-out

It will still be many months before these vaccines have any effect. It is noteworthy that the two vaccine announcements were based on preliminary results. That means that there are still some regulatory hurdles to be crossed, in terms of obtaining final results and obtaining the relevant regulatory approvals. Pfizer, for example, has not at the time of writing released detailed data on efficacy on various age groups.

More than 30% of people may refuse to take the vaccine, due to possible side effects, or based on religious or ethical considerations. I expect a lively debate to emerge in this area, as more details on the vaccines emerge. Concerns are beginning to emerge that the vaccination could cause Antibody-Dependent Enhancement (ADE), where the ability of the virus to enter your body is actually enhanced by the vaccine, resulting in even more severe illness.

Then there are nightmarish logistic hurdles to be crossed, of manufacturing and distributing billions of doses that must be stored at -70°C in the case of the Pfizer vaccine, and 20 below for the Moderna vaccine. Not even the most advanced hospitals like Mayo Clinic have the capacity to store vaccines at -70°C.   

Optimistically, it will be Q2 or Q3 2021 before the vaccines will start making an impact. While there may be a light at the end of the tunnel, there is still a long and dark journey ahead. Until then, we will have a winter of exponential expansion of the virus, massive levels of sickness, suffering, and death.

Economic Effects  

Although we may have some kind of visibility on the epidemiological curve improving in Q2 or Q3 next year, I will argue that we have less visibility on the curve for economic performance and financial markets. On medieval maps, at the edge of the explored world, cartographers would write “tierra de leones” (land of lions).

Any forecaster who tells you what to expect in terms of GDP or financial markets for 2021 is at best making an educated guess. We are into “tierra de leones.”

Why this high degree of uncertainty? The following list is not exhaustive, nor is it placed in order of importance:

• Uncertainty as to timing of fiscal relief, in the United States due to the uncertain handover of power, in Europe due to the recent veto of the EU relief plan;

• Possible civil unrest of unprecedented proportions to lockdowns, or in the States, related to the transfer of power;

• U.S.-Sino conflict continuing to play out;

• Rapidly escalating numbers of bankruptcies as businesses and individuals use up their financial reserves;

• These, in turn, may trigger bank defaults. Potential bank exposure to CDO’s and derivatives remains opaque. Societe Generale, for example has the lowest Price to Tangible Book Value ratio of any bank in Europe, at 17%.

• A U.S. dollar crisis may be triggered by international investors dumping treasury bonds.

Even though the pandemic may begin receding in Q2 or Q3, economic and financial “surprises” may manifest themselves well thereafter, as bankruptcies and their like take time to work through the system.

There are, however, a few things that might be predicted with some degree of confidence. Governments and central banks will continue massive amounts of fiscal and monetary stimulus: globally, there has been USD 19 trillion of COVID relief to date, according to CNN, and that is still going strong. Debt will continue to soar; money supply will continue to balloon.

Assuming the aforementioned scenario, what is the advice to business owners and investors?

Firstly, this is not a sellers’ market for mergers and acquisitions: unless you have a company that is a “winner” from COVID-19, or you are in a rush to sell even on a “distress” basis, it best to wait until at least Q2 before putting your company on the market. (You could, however, use the time to improve your company and prepare it for an eventual sale.)

Secondly, to help survive the upcoming tough winter, ensure you have sufficient liquidity, both at the personal and corporate level.

Thirdly, I continue to believe in gold (up to 5% of your portfolio) as an excellent hedge. While there will, of course, be price fluctuations in this environment of massive fiscal and monetary stimulus, over the long-term gold appears to have much more upside than downside.

The international political, economic and financial order is under unprecedented stress. Systems under stress are likely to produce surprises. Be prepared for the unexpected.

Les Nemethy is a former World Banker, CEO of Euro-Phoenix Financial Advisers Ltd. (www.europhoenix.com), a Central European corporate finance firm, author of Business Exit Planning (www.businessexitplanningbook.com) and a former president of the American Chamber of Commerce in Hungary.

This article was first published in the Budapest Business Journal print issue of November 27, 2020.

ADVERTISEMENT

Wizz Air issues EUR 500 mln bond Transport

Wizz Air issues EUR 500 mln bond

1,438 new COVID-19 cases registered in Hungary Figures

1,438 new COVID-19 cases registered in Hungary

Gov't to roll out PIT exemption for Hungarians under 25 Government

Gov't to roll out PIT exemption for Hungarians under 25

Tourism nights down 85% y.o.y. in November 2020 Tourism

Tourism nights down 85% y.o.y. in November 2020

SUPPORT THE BUDAPEST BUSINESS JOURNAL

Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.